Ajooni Biotech Limited — Results, 17-12-2024: Reply to Clarification- Financial results

**Consolidated Financials**

Ajooni Biotech Limited reported consolidated financial results for the quarter and half-year ended September 30, 2024, showcasing strong performance characterized by robust revenue growth.

**Revenue Growth**

Total revenue from operations reached ₹2,572.44 crore, reflecting a year-over-year increase of approximately 32.0% from ₹1,947.99 crore in the same quarter last year. This growth can be attributed to heightened demand in the biotech sector and successful market expansion initiatives.

**Profit and EPS**

Net profit for the quarter stood at ₹61.51 crore, up from ₹40.47 crore a year ago, marking a year-over-year growth of 52.1%. Earnings Per Share (EPS) improved to ₹0.04 from ₹0.03, indicating effective cost management and increased operational efficiency following operational improvements and reduced employee costs.

**Operational Costs**

Total expenses rose to ₹2,523.93 crore, an increase of 31.2% from ₹1,924.91 crore in the previous year. The cost of materials consumed comprised a significant portion of expenses, totaling ₹2,247.25 crore. Despite higher material costs, Ajooni's effective cost control measures helped improve profit margins.

**Balance Sheet & Cash Flow Statement**

As of September 30, 2024, total assets amounted to ₹8,909.64 crore, with total equity of ₹8,612.44 crore. The company experienced a net cash outflow from operating activities, primarily driven by significant operational cash used and adjustments in working capital components.

**Strategic Position and Outlook**

The company appears focused on enhancing operational efficiency while navigating cost pressures efficiently. The strengthened revenue base and improved profitability might position Ajooni Biotech for potential future expansions, given sustained market demand.

**Investor Insight**

Considering the financial performance and strategic positioning, investors may find Ajooni Biotech to be a hold in their portfolios, given its solid growth trajectory and ongoing operational improvements, balanced with a cautious view on rising operational costs and cash flow management.